| Date | Title | Description |
| 01.07.2026 | Ipsen to acquire Memo Therapeutics for up to EUR 700 million |
French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu... |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 09.01.2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Thu, Jan 09, 2025 09:00 CET Report this content
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 02.11.2023 | Memo Therapeutics Raises CHF 25 Million Series C Financing | |
| 13.04.2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
| 03.05.2022 | Engimmune Therapeutics raises CHF 15.5 million in seed financing | |
| 27.09.2021 | Neuzugänge bei Startup-Supportern und -Investoren | |
| 16.06.2021 | USD67 million for Alentis Therapeutics | Alongside Morningside Venture Investments, Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital joined Alentis’ financing round.
&quo... |
| 16.06.2021 | USD67 million for Alentis Therapeutics | |
| 18.05.2021 | Hummingbird Bioscience : Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 18.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 17.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | |
| 24.04.2021 | Pureos Bioventures Raises Additional USD35M; Fund Totals USD205M | Pureos Bioventures raised further USD35m and closed its first fund, BB Pureos Bioventures, LP, with a committed capital of USD 205m.
The firm had announced a USD170m close in September 2020. The supporters of the first Pureos fund include s... |
| 23.04.2021 | Pureos Bioventures Expands Fund Size to USD 205 Million | The supporters of the first Pureos fund include strategic partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, family offices, pension funds, fund-of-funds and other institutional investors. With ... |
| 23.04.2021 | Pureos Bioventures Expands Fund Size to USD 205 Million | |
| 22.10.2020 | A CHF 15.2 Million seed investment brings Araris Biotech a step further | There are nine antibody-drug conjugates (ADC) approved by the FDA; however, many of them cannot be dosed high enough to elicit efficacy. This is due to systemic toxicity often caused by linker instability or heterogeneous distributions of t... |
| 22.10.2020 | A CHF 15.2 Million seed investment brings Araris Biotech a step further | |
| 23.09.2020 | Pureos Bioventures Closes First Fund, at USD 170M | Pureos Bioventures, a St. Peter Port, Guernsey and Zurich, Switzerland-based newly formed venture capital firm, advised by Bellevue Asset Management, closed its first fund BB Pureos Bioventures LP, with committed capital of USD 170m.
The su... |
| 23.09.2020 | Pureos Bioventures Closes First Fund with USD 170 Million | |
| 23.09.2020 | Pureos Bioventures Closes First Fund with USD 170 Million | The fund BB Pureos Bioventures LP (“Pureos”) was closed with committed capital of USD 170 million. The supporters of the first Pureos fund include strategic limited partners, such as pharmaceutical and biotech companies as well as a large c... |
| 08.06.2020 | Good news for two accelerators | F10 has appointed Gerrit Sindermann as new Head F10 Zurich. Gerrit will join F10 FinTech Incubator & Accelerator mid of June 2020 to lead the mission of guiding start-ups in transforming their ideas into successful companies while stimu... |
| 08.06.2020 | Good news for two accelerators | |
| 30.04.2019 | ALENTIS Therapeutics raises CHF 12.5m in a Series A | |
| 04.03.2019 | Pureos Bioventures invests in first company | |
| 13.02.2018 | Bellevue Asset Management gründet neue Risikokapitalgesellschaft | |
| - | ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer | ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swis... |
